Sculptor Capital LP Takes $21.11 Million Position in OPKO Health, Inc. $OPK

Key Points

• Sculptor Capital LP acquired a new stake in OPKO Health, buying 12,717,400 shares valued at approximately $21.11 million, representing about 1.60% of the company's total stock.
• CEO Phillip Md Et Al Frost purchased 675,000 shares at an average price of $1.32 per share, increasing his total ownership in the company to approximately $283.37 million.
• OPKO Health reported a loss of ($0.19 EPS) for the latest quarter, falling short of analyst expectations, with revenue also declining by 13.9% year-over-year.

Sculptor Capital LP bought a new stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 12,717,400 shares of the biotechnology company's stock, valued at approximately $21,111,000. Sculptor Capital LP owned about 1.60% of OPKO Health at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC lifted its stake in OPKO Health by 68.7% during the fourth quarter. Barclays PLC now owns 916,368 shares of the biotechnology company's stock worth $1,347,000 after purchasing an additional 373,032 shares during the last quarter. SG Americas Securities LLC bought a new stake in OPKO Health in the first quarter valued at $585,000. Vanguard Group Inc. lifted its stake in OPKO Health by 1.0% in the first quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company's stock valued at $48,970,000 after buying an additional 293,740 shares during the last quarter. Bank of America Corp DE lifted its stake in OPKO Health by 94.7% in the fourth quarter. Bank of America Corp DE now owns 581,582 shares of the biotechnology company's stock valued at $855,000 after buying an additional 282,844 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in OPKO Health by 136.1% in the fourth quarter. Two Sigma Investments LP now owns 1,647,567 shares of the biotechnology company's stock valued at $2,422,000 after buying an additional 949,671 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on OPK. Zacks Research upgraded OPKO Health from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. LADENBURG THALM/SH SH raised OPKO Health to a "strong-buy" rating in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $2.75.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $1.32 per share, with a total value of $891,000.00. Following the purchase, the chief executive officer owned 214,676,448 shares of the company's stock, valued at $283,372,911.36. This trade represents a 0.32% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 49.69% of the company's stock.

OPKO Health Price Performance

NASDAQ:OPK traded down $0.02 during mid-day trading on Thursday, reaching $1.37. 478,385 shares of the stock were exchanged, compared to its average volume of 3,701,277. The business has a fifty day moving average price of $1.35 and a 200 day moving average price of $1.45. The firm has a market capitalization of $1.08 billion, a PE ratio of -5.46 and a beta of 1.40. OPKO Health, Inc. has a 1-year low of $1.11 and a 1-year high of $2.04. The company has a current ratio of 3.41, a quick ratio of 3.02 and a debt-to-equity ratio of 0.25.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $165.74 million. OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.OPKO Health's revenue was down 13.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.01) earnings per share. Research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.